
| 2016 | |
|---|---|
| Criterium: | Position: | 
| Overall Score: | > 1000 | 
| Networking Rank (Reputation): | > 1000 | 
| 2008 | |
| Criterium: | Position: | 
| Overall Score: | > 1000 | 
| Networking Rank (Reputation): | > 1000 | 
									Total number of projects: 7
As coordinator: 0
As participant: 7
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2017 | 0 | 25.810.243 | 0 | 3 | ||
| 2016 | 0 | 51.038.522 | 85.000 | 3 | ||
| 2010 | 0 | 11.460.630 | 100.000 | 1 | ||
							Total number of partners: 147
							Partner loyalty:
Frequent Partner: (> 2 projects): 20
Rare Partner: 127
Frequent / Rare Partner Ratio: 0.16
						
| Start date | Project | acronym | role | funding | partners | 
|---|---|---|---|---|---|
| 2017-11-01 | Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections | COMBACTE-CDI | participant | 2.312.305 | 14 | 
| 2017-07-01 | Development of Robust and Innovative Vaccine Effectiveness | DRIVE | participant | 8.999.813 | 15 | 
| 2017-01-01 | REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019 | RESCEU | participant | 14.498.125 | 18 | 
| 2016-03-01 | Vaccine lot to Vaccine lot comparison by consistancy testing - Sofia ref.: 115924 | VAC2VAC | participant | 7.850.000 | 23 | 
| 2016-03-01 | PERtussIS COrrelates of Protection Europe - Sofia ref.: 115910 | PERISCOPE | participant | 21.000.000 | 24 | 
| 2016-01-01 | European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates | EHVA | participant | 22.188.522 | 43 | 
| 2010-11-01 | "Vaccination against Shigella and ETEC: novel antigens, novel approaches" | STOPENTERICS | participant | 11.460.630 | 17 |